ClinicalTrialsFinder
RecruitingNCT06416995

Serum Vasohibin, Cardiotrophin, Endocan & Perinatal Outcomes

Investigation of First Trimester Serum Vasohibin-1, Vasohibin-2, Cardiotrophin-1 and Endocan Concentrations in Predicting Adverse Perinatal Outcomes

Sponsor

Umraniye Education and Research Hospital

Enrollment

88 participants

Start Date

Mar 3, 2023

Study Type

OBSERVATIONAL

Conditions

PreeclampsiaGestational DiabetesPreterm BirthGestational HypertensionFetal Growth Retardation

Summary

Investigation of the relationship between maternal serum vasohibin-1, vasohibin-2, cardiotrophin -1 and endocan concentrations at the 11th and 14th weeks of gestation and adverse perinatal outcomes.

Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 39 Years

Inclusion Criteria5

  • Those who had the first-trimester screening test between 11 and 14 weeks of pregnancy and are in the low-risk group
  • Those with singleton pregnancy
  • Those who did not conceive pregnancy with assisted reproductive treatment methods
  • Those who do not have any pregestational diseases
  • Those who do not have any uterine anomalies

Exclusion Criteria6

  • Smokers
  • Those who are in the high-risk group with the first trimester screening test
  • Those with multiple pregnancies
  • Those who conceive with assisted reproductive treatment methods
  • Those who had any disease before pregnancy
  • Those who have any uterine anomalies

Interventions

DIAGNOSTIC_TESTfirst trimester serum diagnostic test

First trimester serum vasohibin-1, vasohibin-2, cardiotropin-1 and endocan concentrations predict adverse perinatal outcomes

Locations(1)

Ümraniye Eğitim ve Araştırma Hastanesi

Istanbul, Ümraniye, Turkey (Türkiye)

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06416995

Related Trials

Placental Imaging Techniques

NCT068613091 location

Continuous Positive Airway Pressure (CPAP) for Sleep Apnea in Pregnancy

NCT0348718514 locations

A Randomized, Placebo-controlled Trial of DAPAgliflozin (DAPA) for Cardiovascular Risk Reduction in the Postpartum Period of Hypertensive Pregnancies (HP)

NCT067851161 location

Effects of High Altitude on AMPK Activation

NCT023915191 location

Vascular Effects of High-Salt After Preeclampsia

NCT067494181 location